Surgical management of primary hepatic neuroendocrine tumors: A 20-year population-based analysis

IF 2.1 4区医学 Q3 ONCOLOGY

Surgical Oncology-Oxford Pub Date : 2026-02-01 Epub Date: 2026-01-29 DOI:10.1016/j.suronc.2026.102358

Alexandra H. Helbing , Tony Boualoy , Ambria S. Moten

{"title":"Surgical management of primary hepatic neuroendocrine tumors: A 20-year population-based analysis","authors":"Alexandra H. Helbing , Tony Boualoy , Ambria S. Moten","doi":"10.1016/j.suronc.2026.102358","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Primary hepatic neuroendocrine tumors (PHNETs) are rare neoplasms with limited population-level data to guide treatment. We evaluated clinical, pathologic, and treatment factors associated with surgical intervention and survival using a contemporary national cohort.</div></div><div><h3>Methods</h3><div>Patients diagnosed with PHNETs from 2000 to 2021 were identified within the Surveillance, Epidemiology, and End Results (SEER) database. Demographic, tumor, and treatment characteristics were analyzed. Multivariable logistic regression identified predictors of surgical resection. Kaplan-Meier and Cox models evaluated overall survival (OS) and cause-specific survival (CSS).</div></div><div><h3>Results</h3><div>A total of 669 patients met inclusion criteria. Surgical resection was performed in 16.4 % of cases. Compared with localized disease, regional disease was associated with significantly lower odds of surgery (OR 0.25, 95 % CI: 0.14–0.45). Ten-year OS was 21.8 % for localized, 12.5 % for regional, and 4.8 % for distant disease (p < 0.001). Well differentiated tumors were associated with superior 5- and 10-year OS and CSS compared to poorly differentiated tumors (p < 0.001). Among patients with localized or regional disease, surgical resection was associated with a 10-year OS of 44.9 % versus 9.2 % without surgery (p < 0.001). On multivariable analysis, poorly differentiated histology (HR 2.69, 95 % CI: 1.93–3.77) and larger tumor size (HR 1.01, 95 % CI: 1.00–1.01) were associated with increased mortality, while surgical resection remained protective (HR 0.23, 95 % CI: 0.15–0.37).</div></div><div><h3>Conclusions</h3><div>Surgical resection is associated with significantly improved survival in patients with localized or regional PHNETs. Tumor grade, stage, and size remain key prognostic factors in this rare malignancy.</div></div>","PeriodicalId":51185,"journal":{"name":"Surgical Oncology-Oxford","volume":"64 ","pages":"Article 102358"},"PeriodicalIF":2.1000,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Surgical Oncology-Oxford","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0960740426000095","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/29 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Primary hepatic neuroendocrine tumors (PHNETs) are rare neoplasms with limited population-level data to guide treatment. We evaluated clinical, pathologic, and treatment factors associated with surgical intervention and survival using a contemporary national cohort.

Methods

Patients diagnosed with PHNETs from 2000 to 2021 were identified within the Surveillance, Epidemiology, and End Results (SEER) database. Demographic, tumor, and treatment characteristics were analyzed. Multivariable logistic regression identified predictors of surgical resection. Kaplan-Meier and Cox models evaluated overall survival (OS) and cause-specific survival (CSS).

Results

A total of 669 patients met inclusion criteria. Surgical resection was performed in 16.4 % of cases. Compared with localized disease, regional disease was associated with significantly lower odds of surgery (OR 0.25, 95 % CI: 0.14–0.45). Ten-year OS was 21.8 % for localized, 12.5 % for regional, and 4.8 % for distant disease (p < 0.001). Well differentiated tumors were associated with superior 5- and 10-year OS and CSS compared to poorly differentiated tumors (p < 0.001). Among patients with localized or regional disease, surgical resection was associated with a 10-year OS of 44.9 % versus 9.2 % without surgery (p < 0.001). On multivariable analysis, poorly differentiated histology (HR 2.69, 95 % CI: 1.93–3.77) and larger tumor size (HR 1.01, 95 % CI: 1.00–1.01) were associated with increased mortality, while surgical resection remained protective (HR 0.23, 95 % CI: 0.15–0.37).

Conclusions

Surgical resection is associated with significantly improved survival in patients with localized or regional PHNETs. Tumor grade, stage, and size remain key prognostic factors in this rare malignancy.

查看原文本刊更多论文

原发性肝脏神经内分泌肿瘤的外科治疗：一项基于20年人群的分析。

背景：原发性肝神经内分泌肿瘤（PHNETs）是一种罕见的肿瘤，在人群水平上的数据有限，无法指导治疗。我们使用当代国家队列评估了与手术干预和生存率相关的临床、病理和治疗因素。方法：在监测、流行病学和最终结果（SEER）数据库中确定2000年至2021年诊断为PHNETs的患者。分析人口统计学、肿瘤和治疗特点。多变量logistic回归确定了手术切除的预测因素。Kaplan-Meier和Cox模型评估总生存期（OS）和病因特异性生存期（CSS）。结果：669例患者符合纳入标准。16.4%的病例行手术切除。与局部疾病相比，局部疾病与手术的几率显著降低相关（OR: 0.25, 95% CI: 0.14-0.45）。局限性PHNETs的10年总生存率为21.8%，局部疾病为12.5%，远处疾病为4.8%(结论：手术切除与局限性或区域性PHNETs患者的生存率显著提高相关。肿瘤分级、分期和大小仍然是这种罕见恶性肿瘤的关键预后因素。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Surgical Oncology-Oxford 医学-外科

CiteScore

4.50

自引率

0.00%

发文量

169

审稿时长

38 days

期刊介绍： Surgical Oncology is a peer reviewed journal publishing review articles that contribute to the advancement of knowledge in surgical oncology and related fields of interest. Articles represent a spectrum of current technology in oncology research as well as those concerning clinical trials, surgical technique, methods of investigation and patient evaluation. Surgical Oncology publishes comprehensive Reviews that examine individual topics in considerable detail, in addition to editorials and commentaries which focus on selected papers. The journal also publishes special issues which explore topics of interest to surgical oncologists in great detail - outlining recent advancements and providing readers with the most up to date information.